GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
The China National Medical Products Association (NMPA) has approved AstraZeneca's Fasenra (benralizumab) as a maintenance treatment for individuals aged 12…
The approval of Regeneron and Sanofi’s Dupixent (dupilumab) as the first targeted therapy for chronic obstructive pulmonary disease (COPD) has…
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) and European Commission (EC) approvals for SIRTURO (bedaquiline)…
Aerovate Therapeutics is slashing its workforce by 78%, two weeks after the company announced a Phase IIb trial failure of…
The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive…
Six months after kicking off a Phase I trial for idiopathic pulmonary fibrosis (IPF) treatment AGMB-447, Agomab Therapeutics has now…
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of CStone's sugemalimab,…
Moderna has secured approval from the US Food and Drug Administration (FDA) for its mRNA-based respiratory syncytial virus (RSV) vaccine…
Amgen and AstraZeneca have highlighted the potential of Tezspire (tezepelumab) in chronic obstructive pulmonary disease (COPD) in a subgroup of…